ClinicalTrials.gg
CompletedNCT02902679Updated Jul 27, 2017

A Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Participants With End-stage Renal Dysfunction on Chronic Stable Hemodialysis Treatment

A Phase 1 interventional study of BMS-986177 in Thrombosis, Factor XI and Renal Impairment, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-07-27.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Thrombosis by Bristol-Myers Squibb — none open to participants now, none under way, none of them phase 3. Thrombosis · Bristol-Myers Squibb.

Enrollment
19th of 19
6 · median 42
Started
2016
with 3 others
Phase 1
13 of 19
none open now
Registered
10th of 19
by date

Among the 19 studies in Thrombosis by Bristol-Myers Squibb, this one is the 19th largest by enrollment, is one of 4 that started in 2016, is one of 13 in phase 1, and was the 10th registered.

Thrombosis

955 studies on the registry are indexed under Thrombosis; 171 are open to participants now.

Browse Thrombosis studies →

Open to participants now

None of the 19 studies in Thrombosis by Bristol-Myers Squibb is open now. The open studies under Thrombosis, anywhere →

Who these studies take

Of the 126 Thrombosis studies recruiting now, 79 (63%) set no upper age limit and 16 (13%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Thrombosis by Bristol-Myers Squibb as a file.
02

Study summary

An oral dose of BMS-986177 administered in End-stage Renal Dysfunction (ESRD) participants before and after a hemodialysis session to evaluate safety, tolerability, and pharmacokinetics in this patient population.

03

Conditions studied

  • Thrombosis
  • Factor XI
  • Renal Impairment
  • ESRD (End-Stage Renal Disease)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Classified at screening as having ESRD requiring hemodialysis at least 3 times per week for 3 months.
  • Clinical, , and laboratory findings consistent with renal dysfunction
  • of 18.0 to 38.0 kg/m2 inclusive
  • Subjects must receive unfractionated heparin during dialysis treatments and are able to withstand a decrease in their established heparin dose (75% of current dose)
  • Women Not of child bearing potential (WNOCBP). Sexually active fertile men with partners who are must use non-hormonal highly effective

Exclusion criteria

Exclusion Criteria:

  • History of uncontrolled or unstable cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematopoietic, psychiatric, and/or neurological disease within 6 months of screening
  • Evidence or history of coagulopathy, prolonged or unexplained bleeding, or frequent unexplained bruising
  • Current or recent (within 3 months of study drug administration) clinically significant gastrointestinal disease or gastrointestinal surgery that could interfere with absorption of study drug
  • Any condition requiring anticoagulation such as, but not limited to, atrial fibrillation, mechanical prosthetic valve, deep venous thrombosis, or pulmonary embolism (other than heparin required during hemodialysis)
  • Need for aspirin or need for P2Y12 antagonist therapy (for example clopidogrel, prasugrel, or ticagrelor)
  • Other protocol defined exclusion criteria could apply
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    End Stage Renal Disease Subjects

    Subjects given a single oral dose of BMS-986177 before (Period 1) and after (Period 2) a hemodialysis session

    Drug: BMS-986177

Interventions

06

What researchers measure

Primary outcomes

  1. To assess the Number of subjects with Adverse events (AEs).

    Time frame: Day -1 - day 3

  2. To assess the Change from baseline in Physical examination parameters.

    Time frame: Day -1 - day 3

  3. To assess the change from baseline in Electrocardiogram (ECG) assessment.

    Time frame: Day -1 - day 3

  4. To assess the change from baseline in clinical laboratory values.

    Time frame: Day -1 - day 3

  5. To assess the change from baseline in vital signs assessment.

    Time frame: Day -1 - day 3

Secondary outcomes

  1. To assess the change from baseline in activated partial thromboplastin time (aPTT).

    Time frame: Day -1 - day 3

  2. To assess the change from baseline in Factor XI clotting activity (FX1c ).

    Time frame: Day -1 - day 3

07

Study locations

1 site
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Jun 2017, 7 months.

Of 30 phase 1 interventional studies under Thrombosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 30. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2016
First posted
Sep 16, 2016
StartActual
Nov 2016
Primary completionActual
Jun 2017
CompletionActual
Jun 2017
Last update
Jul 27, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02902679
Responsible party
Sponsor
First posted
Sep 16, 2016
Start date
Nov 2016
Primary completion
Jun 2017
Completion
Jun 2017
Last update
Jul 27, 2017

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Milvexian

Start the discussion